TILVANCE-301 trial: what clinicians have said so far
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- NCT05727904 ↗
- Recruiting
- Iovance Biotherapeutics, Inc.
- Deep size, estimated: 301+ verified statements once built
Discussed at: ESMO Congress 2026
We haven't built an HCP commentary report on TILVANCE-301 (lifileucel plus pembrolizumab in untreated unresectable or metastatic melanoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TILVANCE-301 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 40 posts on X, typically up to 176 once built | |
| 3 YouTube videos, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Melanoma; Unresectable Melanoma; Melanoma
- Interventions
- Lifileucel plus Pembrolizumab; Pembrolizumab with Optional Crossover Period
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Enrollment
- 670 (estimated)
- Primary outcomes
- Objective Response Rate and Progression Free Survival
- Sponsor
- Iovance Biotherapeutics, Inc.
- Start
- Mar 30, 2023
- Primary completion
- Mar 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05727904 · updated Sep 24, 2026